Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Share Price: 1608.68 pence per Share (as of April 9, 2015).
- Transaction Type: Reinvestment of dividends via the GSK ShareReward Plan.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details specific share acquisitions by company leadership rather than operational or financial shifts.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of insider trading activity.
Important Facts for Investors
- Transaction Date: Shares were acquired on April 9, 2015.
- Participants: Acquisitions were made by Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Volume: Total shares acquired by the listed individuals ranged from 9 to 58 shares each.
- Mechanism: All transactions resulted from dividend reinvestment, not open market purchases.